Heart Failure

Cardiomyopathy.

Expert second opinions for cardiomyopathy. Dual-physician Heart Team review with triple risk scoring. Results in 24 hours.

HCM: 1 in 500; DCM: 1 in 250
Prevalence
Variable by type and severity
Key Outcome
Myectomy mortality <1% at expert centers
Procedures
Quick Answer

Cardiomyopathy encompasses diseases of the heart muscle that impair its ability to pump blood effectively. If you are facing a decision about cardiomyopathy, an independent Heart Team second opinion can confirm whether surgery is the right choice and identify alternatives. WhiteGloveMD delivers dual-physician review with STS, EuroSCORE II, and AATS risk scoring in 24 hours. Get an independent second opinion →

Overview

Understanding cardiomyopathy.

Cardiomyopathy encompasses diseases of the heart muscle that impair its ability to pump blood effectively. Dilated cardiomyopathy (DCM) involves ventricular enlargement and weakening, hypertrophic cardiomyopathy (HCM) involves abnormal thickening, and restrictive cardiomyopathy involves stiffening of the heart wall.

Why It Matters

Why you need a second opinion.

Each type of cardiomyopathy has different treatment algorithms and surgical options. HCM may benefit from septal myectomy, DCM may require LVAD or transplant evaluation, and the diagnosis itself may change management. Genetic testing implications for family members add another layer of complexity.

Critical Decisions

Key decisions for cardiomyopathy.

Accurate diagnosis and classification
HCM: septal myectomy vs alcohol septal ablation
DCM: reversible causes workup and advanced therapy timing
Genetic testing and family screening implications
Device therapy (ICD, CRT) candidacy
Risk Factors

What affects your risk.

Genetic mutations and family screening
Sudden cardiac death risk stratification
Arrhythmia burden
LVOT obstruction severity in HCM
Response to medical therapy
Our Review

What our Heart Team provides.

Dual-physician review (cardiac surgeon + cardiologist)
Triple risk scoring (STS PROM, EuroSCORE II, AATS)
ACC/AHA guideline mapping with evidence grades
Treatment alternatives with risk-benefit comparison
Surgeon and institution matching via Sentinel
Personalized question guide for your next appointment
Complete provenance trail for every conclusion
Results delivered within 24 hours
Common Questions

Frequently asked questions.

Do I need surgery for cardiomyopathy?

Surgery for cardiomyopathy depends on symptom severity, imaging findings, and risk profile. Guidelines from the AHA/ACC define specific thresholds, but many patients fall into gray zones where a second opinion meaningfully changes the recommendation. Each type of cardiomyopathy has different treatment algorithms and surgical options. HCM may benefit from septal myectomy, DCM may require LVAD or transplant evaluation, and the diagnosis itself may change management. Genetic testing implications for family members add another layer of complexity.

What are the risks of cardiomyopathy surgery?

Operative mortality for cardiomyopathy-related cardiac surgery is calculated using validated models including STS PROM, EuroSCORE II, and AATS. Individual risk depends on age, comorbidities, frailty, ejection fraction, and surgeon/center volume. Our free calculator at whiteglovemd.com/tools/risk-calculator estimates your specific risk across all three models in real time.

Should I get a second opinion before cardiomyopathy surgery?

Yes. Studies show that 30-40% of expert cardiac surgery second opinions change the original treatment plan — sometimes by recommending less-invasive alternatives, sometimes by clarifying that watchful waiting is safer. WhiteGloveMD pairs a cardiac surgeon and cardiologist with our Clintelligence multi-agent AI pipeline to deliver an independent review in 24 hours, starting at $500.

What is the best treatment for cardiomyopathy?

The optimal treatment for cardiomyopathy depends on anatomy, comorbidities, age, and personal goals. Accurate diagnosis and classification. A Heart Team review evaluates every viable option — including transcatheter approaches, repair vs replacement, and surgeon/center matching — rather than defaulting to a single recommendation.

Clinical References
  1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
  2. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report (MOMENTUM 3). N Engl J Med. 2019;380(17):1618-1627.
  3. O'Brien SM, Feng L, He X, et al. The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models. Ann Thorac Surg. 2018;105(5):1411-1418.
  4. Nashef SAM, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41(4):734-745.

Related conditions.

Heart Failure
Hypertrophic Cardiomyopathy
LVAD (Left Ventricular Assist Device)
Heart Transplant Evaluation
Septal Myectomy

Get an expert opinion on your cardiomyopathy.

WhiteGloveMD delivers a dual-physician, AI-augmented second opinion in 24 hours. Starting at $500.

Start Your Review Try the Risk Calculator